New Harvard spin-out blood pathogen-extracting device developer Opsonix said it raised $8 million in its Series A round upon launching, led by Baxter (NYSE:BAX) Ventures. Opsonix is developing a device to remove infectious pathogens and toxins from circulating blood, to treat blood-borne infectious diseases,including sepsis, the Cambridge, Mass.-based company said. “Opsonix’s pathogen-extracting therapy provides a novel […]